Achieve Life Sciences Sees Unusually Large Options Volume (NASDAQ:ACHV)

Achieve Life Sciences, Inc. (NASDAQ:ACHV) was the target of unusually large options trading activity on Tuesday. Stock traders purchased 2,079 call options on the stock. This is an increase of 175% compared to the typical daily volume of 756 call options.

Hedge Funds Weigh In On Achieve Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. raised its position in Achieve Life Sciences by 18,747.4% during the 4th quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock worth $21,715,000 after buying an additional 4,346,011 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Achieve Life Sciences in the second quarter worth $2,652,000. Millennium Management LLC increased its stake in shares of Achieve Life Sciences by 472.3% in the fourth quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after acquiring an additional 1,121,614 shares during the period. Pathstone Holdings LLC purchased a new position in shares of Achieve Life Sciences during the third quarter worth $1,581,000. Finally, KVP Capital Advisors LP purchased a new position in shares of Achieve Life Sciences during the fourth quarter worth $2,298,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

More Achieve Life Sciences News

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: Achieve announced a manufacturing partnership with U.S.-based Adare Pharma Solutions for cytisinicline, reducing supply-chain risk ahead of potential commercialization and de‑risking scale-up needs. Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
• Positive Sentiment: Options activity was unusually high (notably increased call volume), indicating elevated speculative/bullish interest that can amplify intraday moves and volatility. (No article link available.)
• Neutral Sentiment: Q4 results were essentially in line with expectations but showed a slight EPS miss (reported -$0.28 vs. consensus -$0.27), so operating performance didn’t materially beat estimates. This explains mixed investor reactions to the print. Achieve Life Sciences Inc (ACHV) Q4 2025 Earnings Call Highlights: Strategic Advances and …
• Neutral Sentiment: Management held an earnings call and the transcript is available for details on program timelines and commercialization plans — useful for tracking upcoming clinical or regulatory catalysts. Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Multiple short-interest notices in data feeds cite a “significant increase,” but the published figures are inconsistent/zero (NaN/0 shares), suggesting a reporting/data error rather than clear new shorting pressure; treat these reports cautiously.
• Negative Sentiment: Law firm Johnson Fistel announced an investigation into potential claims against Achieve executives, which introduces legal/insider scrutiny risk and can weigh on investor sentiment until resolved. Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Analysts Set New Price Targets

ACHV has been the subject of a number of recent analyst reports. Citigroup initiated coverage on Achieve Life Sciences in a research report on Tuesday, November 25th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. Finally, Citizens Jmp initiated coverage on Achieve Life Sciences in a research note on Tuesday, November 25th. They issued a “market outperform” rating and a $19.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Achieve Life Sciences Price Performance

Shares of ACHV opened at $2.90 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.14 and a quick ratio of 5.14. The company’s fifty day moving average price is $4.49 and its 200-day moving average price is $4.31. Achieve Life Sciences has a 1-year low of $1.84 and a 1-year high of $6.03. The firm has a market capitalization of $154.38 million, a PE ratio of -2.10 and a beta of 1.81.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). On average, equities research analysts predict that Achieve Life Sciences will post -1.17 EPS for the current year.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.